A detailed history of Clarius Group, LLC transactions in Dexcom Inc stock. As of the latest transaction made, Clarius Group, LLC holds 2,328 shares of DXCM stock, worth $156,627. This represents 0.02% of its overall portfolio holdings.

Number of Shares
2,328
Previous 2,416 3.64%
Holding current value
$156,627
Previous $335,000 21.49%
% of portfolio
0.02%
Previous 0.02%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 11, 2024

SELL
$110.31 - $140.45 $9,707 - $12,359
-88 Reduced 3.64%
2,328 $263,000
Q1 2024

Apr 17, 2024

SELL
$114.22 - $140.1 $42,946 - $52,677
-376 Reduced 13.47%
2,416 $335,000
Q4 2023

Jan 29, 2024

SELL
$75.49 - $124.16 $16,683 - $27,439
-221 Reduced 7.33%
2,792 $346,000
Q3 2023

Oct 19, 2023

SELL
$86.06 - $137.93 $87,350 - $139,998
-1,015 Reduced 25.2%
3,013 $281,000
Q2 2023

Aug 09, 2023

SELL
$112.47 - $130.98 $2,474 - $2,881
-22 Reduced 0.54%
4,028 $517,000
Q1 2023

Apr 17, 2023

SELL
$104.0 - $122.92 $832 - $983
-8 Reduced 0.2%
4,050 $470,000
Q4 2022

Jan 25, 2023

BUY
$84.98 - $122.67 $9,432 - $13,616
111 Added 2.81%
4,058 $460,000
Q3 2022

Oct 24, 2022

SELL
$76.35 - $94.18 $9,162 - $11,301
-120 Reduced 2.95%
3,947 $318,000
Q2 2022

Aug 10, 2022

BUY
$67.99 - $132.89 $234,089 - $457,540
3,443 Added 551.76%
4,067 $303,000
Q4 2021

Feb 02, 2022

BUY
$129.87 - $162.82 $11,298 - $14,165
87 Added 16.2%
624 $335,000
Q3 2021

Oct 18, 2021

BUY
$106.71 - $143.18 $4,908 - $6,586
46 Added 9.37%
537 $294,000
Q2 2021

Aug 06, 2021

BUY
$80.99 - $107.93 $39,766 - $52,993
491 New
491 $210,000
Q4 2020

Jan 15, 2021

SELL
$78.0 - $104.5 $46,332 - $62,073
-594 Closed
0 $0
Q3 2020

Oct 09, 2020

BUY
$95.51 - $112.95 $56,732 - $67,092
594 New
594 $245,000

Others Institutions Holding DXCM

About DEXCOM INC


  • Ticker DXCM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 386,257,984
  • Market Cap $26B
  • Description
  • DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM ...
More about DXCM
Track This Portfolio

Track Clarius Group, LLC Portfolio

Follow Clarius Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Clarius Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Clarius Group, LLC with notifications on news.